Cachexia Pipeline: 27+ Innovators Advancing Anti-Wasting and Metabolic Therapies | DelveInsight

Cachexia, a multifactorial syndrome marked by severe muscle wasting and weight loss, especially in cancer and chronic illnesses, has attracted growing R&D interest. Over 27 key companies, including Helsinn, Pfizer, Bristol Myers Squibb, Actimed Therapeutics, and Aeterna Zentaris, are actively working to address this high-burden condition. The pipeline features ghrelin receptor agonists, anabolic/catabolic modulators, selective androgen receptor modulators (SARMs), anti-inflammatory agents, and metabolic regulators.

These therapies aim to improve appetite, restore lean body mass, reduce inflammation, and enhance patient strength and function. With no approved treatments specifically for cachexia, this pipeline represents a vital shift toward integrated supportive care-offering hope to millions of patients suffering from chronic disease-related wasting.

DelveInsight's "Cachexia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the cachexia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging cachexia drugs, the cachexia pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for cachexia and uncover key opportunities @ https://www.delveinsight.com/report-store/cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cachexia Pipeline Report
• DelveInsight's cachexia pipeline analysis depicts a strong space with 27+ active players working to develop 27+ pipeline drugs for cachexia treatment.
• The leading cachexia companies include Tvardi Therapeutics, TMS Co. Ltd, RaQualia Pharma, Pfizer, Pephexia Therapeutics, Oncocross, NGM Biopharmaceuticals, MGC Pharmaceuticals, Keros Therapeutics, Incyte Corporation, ImmunoForge, Immuneering Corporation, Green Cross Wellbeing, GlaxoSmithKline, Faraday Pharmaceuticals, Extend Biosciences, Energenesis Biomedica, Endevica Bio, CNBX Pharmaceuticals, CatalYm, Caelus Health, AVEO Oncology, Artelo Biosciences, Aphios Corporation, AliveGen, AEterna Zentaris, Actimed Therapeutics, AAVogen, and others are evaluating their lead assets to improve the cachexia treatment landscape.
• Key cachexia pipeline therapies in various stages of development include TTI 101, TMS-008, RQ-00433412, PF 06946860, peptide-based pharmacotherapies (research programme), OC514, NGM120, Tetrinol, ligand traps (research programme), Ruxolitinib, PF-1801, Cancer Cachexia (research programme), GCBWB204, GSK2881078, ACM-002, EXT418, EOM613, ENERGI-F704, TCMCB07, Cannabics capsules, CTL-002, CH-0701, AV-380, ART27.13, APH-0802, novel Biotherapeutics (research programme), and others.
• In September 2024, Pfizer Inc. (NYSE: PFE) announced that its Phase II study of ponsegromab, a monoclonal antibody targeting GDF-15, met its primary endpoint, showing a significant change in body weight from baseline in cancer cachexia patients with elevated GDF-15 levels compared to placebo. Cachexia, a life-threatening condition, severely impacts patients' quality of life. The results were presented as a late-breaking Proffered Paper (LBA82) at the 2024 ESMO Congress and published in The New England Journal of Medicine (NEJM).

Request a sample and discover the recent breakthroughs happening in the cachexia pipeline landscape @ https://www.delveinsight.com/report-store/cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cachexia Overview
Cachexia, also known as wasting syndrome, is a complex metabolic disorder associated with chronic illnesses and marked primarily by the loss of skeletal muscle mass, with or without fat loss. It is frequently accompanied by anorexia, systemic inflammation, insulin resistance, and increased protein degradation. This debilitating condition often arises in the advanced stages of serious diseases such as cancer, HIV/AIDS, chronic obstructive pulmonary disease (COPD), kidney disease, and congestive heart failure (CHF).

In cachexia, the body responds to inadequate nutritional intake by breaking down skeletal muscle and fat for energy. Tumor-induced metabolic alterations further disrupt nutritional balance, worsening the patient's overall condition. This leads to a weakened immune system, reduced tolerance to treatments like chemotherapy and radiotherapy, and progressive physical decline. Additionally, cachexia is often associated with a decline in anabolic hormones such as growth hormone, insulin-like growth factor-1 (IGF-1), testosterone, and ghrelin, further exacerbating muscle wasting and weight loss.
Find out more about cachexia medication @ https://www.delveinsight.com/report-store/cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cachexia Treatment Analysis: Drug Profile
GCBWB204: Green Cross Wellbeing
GCBWB204 (BST-204) is an innovative drug candidate for cancer cachexia, a condition that causes muscular atrophy and metabolic disturbances in cancer patients. Utilizing GC Wellbeing's proprietary Bio-Transformation Technology, BST204 has been shown to enhance specific saponin components, providing therapeutic benefits in reducing muscle loss, improving exercise capacity, and mitigating inflammation and hematopoietic toxicity associated with cancer cachexia. BST204 has undergone safety testing in non-clinical toxicity studies in Canada and clinical trials in Europe. The drug exhibits multimodal action by inhibiting muscle degradation and inflammatory cytokines while promoting muscle growth. Green Cross Wellbeing holds patent protection for the pharmaceutical composition and manufacturing method of GCBWB204 in South Korea. The company has successfully completed Phase II clinical trials of GCBWB204 in patients with non-small cell lung cancer and digestive cancers in Europe.

AV-380: AVEO Oncology
AVEO's AV-380 is a preclinical, first-in-class, potent humanized inhibitory antibody that targets growth differentiation factor 15 (GDF15), a pro-inflammatory cytokine whose elevated levels are linked to cachexia in cancer patients. This condition, characterized by severe weight loss due to muscle and fat tissue depletion, is accompanied by anemia, inflammation, and immune system suppression. Preclinical data suggest that inhibiting GDF15 shifts the body's metabolism from catabolism to anabolism, which may reverse the symptoms of cachexia. AVEO has regained the rights to the AV-380 program, which is being explored for the treatment of cachexia, a condition affecting approximately 5 million Americans with advanced cancer and other chronic illnesses. The company is planning to initiate preclinical toxicology studies and is considering various development pathways, including filing an Investigational New Drug application with the FDA.

Learn more about the novel and emerging cachexia pipeline therapies @ https://www.delveinsight.com/report-store/cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cachexia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cachexia Pipeline Report
• Coverage: Global
• Key Cachexia Companies: Tvardi Therapeutics, TMS Co. Ltd, RaQualia Pharma, Pfizer, Pephexia Therapeutics, Oncocross, NGM Biopharmaceuticals, MGC Pharmaceuticals, Keros Therapeutics, Incyte Corporation, ImmunoForge, Immuneering Corporation, Green Cross Wellbeing, GlaxoSmithKline, Faraday Pharmaceuticals, Extend Biosciences, Energenesis Biomedica, Endevica Bio, CNBX Pharmaceuticals, CatalYm, Caelus Health, AVEO Oncology, Artelo Biosciences, Aphios Corporation, AliveGen, AEterna Zentaris, Actimed Therapeutics, AAVogen, and others.
• Key Cachexia Pipeline Therapies: TTI 101, TMS-008, RQ-00433412, PF 06946860, peptide-based pharmacotherapies (research programme), OC514, NGM120, Tetrinol, ligand traps (research programme), Ruxolitinib, PF-1801, Cancer Cachexia (research programme), GCBWB204, GSK2881078, ACM-002, EXT418, EOM613, ENERGI-F704, TCMCB07, Cannabics capsules, CTL-002, CH-0701, AV-380, ART27.13, APH-0802, novel Biotherapeutics (research programme), and others.

Dive deep into rich insights for drugs used for cachexia treatment; visit @ https://www.delveinsight.com/report-store/cachexia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cachexia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cachexia Pipeline Therapeutics
6. Cachexia Pipeline: Late-Stage Products (Phase III)
7. Cachexia Pipeline: Mid-Stage Products (Phase II)
8. Cachexia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.